Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y5WA
|
|||
| Former ID |
DNC013051
|
|||
| Drug Name |
Bip-tyr-thr-pro-lys-thr(obzl)-gly
|
|||
| Synonyms |
CHEMBL428483; bip-tyr-thr-pro-lys-thr(obzl)-gly
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C55H71N9O13
|
|||
| Canonical SMILES |
CC(C(C(=O)N1CCCC1C(=O)NC(CCCCN)C(=O)NC(C(C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC=C(C=C4)C5=CC=C(C=C5)CC(C(=O)O)N)N)O
|
|||
| InChI |
1S/C55H71N9O13/c1-32(65)47(54(74)64-26-8-12-45(64)52(72)60-43(11-6-7-25-56)50(70)63-48(53(73)59-30-46(67)68)33(2)77-31-37-9-4-3-5-10-37)62-51(71)44(29-36-17-23-40(66)24-18-36)61-49(69)41(57)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(58)55(75)76/h3-5,9-10,13-24,32-33,41-45,47-48,65-66H,6-8,11-12,25-31,56-58H2,1-2H3,(H,59,73)(H,60,72)(H,61,69)(H,62,71)(H,63,70)(H,67,68)(H,75,76)/t32-,33-,41+,42+,43+,44+,45+,47+,48+/m1/s1
|
|||
| InChIKey |
WVGBZWZFWUOODF-QHLFIVFVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine transporter (DAT) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Dopaminergic synapse | |||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Dopaminergic Neurogenesis | ||||
| Parkinsons Disease Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Neurotransmitter Clearance In The Synaptic Cleft | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.